Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry
-
Published:2024-02
Issue:2
Volume:24
Page:103-111
-
ISSN:1526-8209
-
Container-title:Clinical Breast Cancer
-
language:en
-
Short-container-title:Clinical Breast Cancer
Author:
Ibragimova Khava I.E.ORCID,
Geurts Sandra M.E.,
Laczkó Dávid,
Meegdes Marissa,
Erdkamp Frans,
Heijns Joan B.,
Tol Jolien,
Vriens Birgit E.P.J.,
Aaldering Kirsten N.A.,
Dercksen Marcus W.,
Pepels Manon J.A.E.,
Peters Natascha A.J.B.,
van de Winkel Linda M.H.,
van de Wouw Agnes J.,
de Fallois Aude,
van Kats Maartje A.C.E.,
Tjan-Heijnen Vivianne C.G.
Funder
Eli Lilly and Company
Novartis Pharma BV
Roche
Pfizer BV
ZonMw
Subject
Cancer Research,Oncology
Reference23 articles.
1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989
2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Eng J Med,2001
3. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group;Marty;J Clin Oncol,2005
4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2020
5. Clinicopathological features among patients with advanced human epidermal growth factor–2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study;Vaz-Luis;Clin Breast Cancer,2013